Showing 4,041 - 4,060 results of 11,357 for search 'significantly ((((lower decrease) OR (we decrease))) OR (((greater decrease) OR (mean decrease))))', query time: 0.64s Refine Results
  1. 4041
  2. 4042
  3. 4043

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  4. 4044

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  5. 4045

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  6. 4046

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  7. 4047

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  8. 4048
  9. 4049

    Prediction of transition readiness. by Sharon Barak (4803966)

    Published 2025
    “…In most transition domains, help needed did not decrease with age and was not affected by function. …”
  10. 4050
  11. 4051

    Baseline analysis, nominal factors. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  12. 4052

    Minimal dataset for the study. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  13. 4053

    Baseline analysis, continuous factors. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  14. 4054

    Multivariable analysis between 2006 and 2018. by Hiroaki Yoshikawa (4615801)

    Published 2025
    “…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”
  15. 4055

    OVX educes bone density of femur. by Mingzhu Chen (6370013)

    Published 2025
    “…Compared to Sham rats, OVX tats had a significant decrease in bone mass and impaired bone micro structure: (L) BMD, (M) BV, (N) BV/TV, (O) Tb.N,(P) Tb.Sp, and (Q) Tb.Th. …”
  16. 4056

    <b> </b> Energy efficiency and gas volume comparison. by Ning Zuo (17295415)

    Published 2025
    “…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
  17. 4057

    Model validation of kinetic parameters. by Ning Zuo (17295415)

    Published 2025
    “…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”
  18. 4058

    Dataset visualization diagram. by Yaojun Zhang (389482)

    Published 2025
    “…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
  19. 4059

    Dataset sample images. by Yaojun Zhang (389482)

    Published 2025
    “…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”
  20. 4060

    Performance comparison of different models. by Yaojun Zhang (389482)

    Published 2025
    “…Results on a specialized dataset reveal that YOLOv8n-BWG outperforms YOLOv8n by increasing the mean Average Precision (mAP) by 4.2%, boosting recognition speed by 21.3% per second, and decreasing both the number of floating-point operations (FLOPs) by 28.9% and model size by 26.3%. …”